Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with a history of prostate cancer (PC), radiographic evidence of...
Main Authors: | Raquibul Hannan, Michael J. Dohopolski, Laurentiu M. Pop, Samantha Mannala, Lori Watumull, Dana Mathews, Ang Gao, Aurelie Garant, Yull E. Arriaga, Isaac Bowman, Jin-Sung Chung, Jing Wang, Kiyoshi Ariizumi, Chul Ahn, Robert Timmerman, Kevin Courtney |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/6/1419 |
Similar Items
-
Immune Response to Sipuleucel-T in Prostate Cancer
by: David I. Quinn, et al.
Published: (2012-04-01) -
The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T
by: John Araujo, et al.
Published: (2013-05-01) -
Stereotactic ablative radiotherapy for primary renal cell carcinoma
by: Daniel X. Yang, et al.
Published: (2024-01-01) -
Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis
by: D. Baron, et al.
Published: (2024-03-01) -
A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer
by: Roberta Coletti, et al.
Published: (2021-12-01)